当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2018-01-10 , DOI: 10.1056/nejmoa1708831 Dirk Bassler 1 , Eric S. Shinwell 1 , Mikko Hallman 1 , Pierre-Henri Jarreau 1 , Richard Plavka 1 , Virgilio Carnielli 1 , Christoph Meisner 1 , Corinna Engel 1 , Alexander Koch 1 , Karen Kreutzer 1 , Johannes N. van den Anker 1 , Matthias Schwab 1 , Henry L. Halliday 1 , Christian F. Poets 1
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2018-01-10 , DOI: 10.1056/nejmoa1708831 Dirk Bassler 1 , Eric S. Shinwell 1 , Mikko Hallman 1 , Pierre-Henri Jarreau 1 , Richard Plavka 1 , Virgilio Carnielli 1 , Christoph Meisner 1 , Corinna Engel 1 , Alexander Koch 1 , Karen Kreutzer 1 , Johannes N. van den Anker 1 , Matthias Schwab 1 , Henry L. Halliday 1 , Christian F. Poets 1
Affiliation
|
Among surviving extremely preterm infants, the rate of neurodevelopmental disability at 2 years did not differ significantly between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, but the mortality rate was higher among those who received budesonide. (Funded by the European Union and Chiesi Farmaceutici; ClinicalTrials.gov number, NCT01035190.)
中文翻译：
吸入布地奈德对支气管肺发育不良的长期影响
在存活的极早产儿中，接受早期吸入布地奈德预防支气管肺发育不良的婴儿和接受安慰剂的婴儿在2岁时的神经发育残疾率没有显着差异，但接受布地奈德的死亡率更高。（由欧盟和Chiesi Farmaceutici资助； ClinicalTrials.gov编号，NCT01035190。）
更新日期：2018-01-11
中文翻译：
吸入布地奈德对支气管肺发育不良的长期影响
在存活的极早产儿中，接受早期吸入布地奈德预防支气管肺发育不良的婴儿和接受安慰剂的婴儿在2岁时的神经发育残疾率没有显着差异，但接受布地奈德的死亡率更高。（由欧盟和Chiesi Farmaceutici资助； ClinicalTrials.gov编号，NCT01035190。）
京公网安备 11010802027423号